Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1994 Jul;70(1):29–34. doi: 10.1038/bjc.1994.245

Efficacy of ifosfamide, dacarbazine, doxorubicin and cisplatin in human sarcoma xenografts.

W Budach 1, V Budach 1, M Stuschke 1, B Schmauder 1, P Reipke 1, M E Scheulen 1
PMCID: PMC2033321  PMID: 8018537

Abstract

The primary chemosensitivity of 16 highly malignant xenografted human soft-tissue sarcomas to ifosfamide, dacarbazine, adriamycin and cisplatin and the development of secondary drug resistance in two chemosensitive sarcoma cell lines was tested in the xenograft system. Single-dose, single-agent treatments with 350 mg kg-1 ifosfamide, 200 mg kg-1 dacarbazine, 10 mg kg-1 doxorubicin and 6.6 mg kg-1 cisplatin were administered and response measured as specific growth delay. Since ifosfamide induced unexpectedly higher toxicity, response was corrected based on the shape of the dose-response curve for ifosfamide. Taking a specific growth delay > 3 as the cut-off point for chemosensitivity, ifosfamide, dacarbazine, doxorubicin and cisplatin were effective in 10/16, 4/16, 2/16 and 1/16 sarcoma cell lines respectively. Five out of 16 sarcoma cell lines were resistant to all tested drugs. Ifosfamide-resistant sarcoma lines were also resistant to doxorubicin and cisplatin, indicating a high degree of cross-resistance. Dacarbazine was still effective in 1/6 ifosfamide-resistant sarcoma cell lines. Secondary drug resistance developed slowly after doxorubicin and ifosfamide pretreatments at moderate selection pressure and developed rapidly after dacarbazine pretreatment at high selection pressure.

Full text

PDF
29

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aamdal S., Fodstad O., Kaalhus O., Pihl A. Chemosensitivity profiles of human cancers assessed by the 6-day SRC assay on serially xenografted tumors. Int J Cancer. 1986 Apr 15;37(4):579–587. doi: 10.1002/ijc.2910370417. [DOI] [PubMed] [Google Scholar]
  2. Antman K. H., Montella D., Rosenbaum C., Schwen M. Phase II trial of ifosfamide with mesna in previously treated metastatic sarcoma. Cancer Treat Rep. 1985 May;69(5):499–504. [PubMed] [Google Scholar]
  3. Boven E., Calame J. J., Molthoff C. F., Pinedo H. M. Characterization and chemotherapy of human soft tissue sarcoma (STS) lines grown in nude mice. Strahlenther Onkol. 1989 Jul;165(7):538–539. [PubMed] [Google Scholar]
  4. Bramwell V. H., Brugarolas A., Mouridsen H. T., Cheix F., De Jager F., van Oosterom A. T., Vendrik C. P., Pinedo H. M., Sylvester R., De Pauw M. E.O.R.T.C. phase II study of cisplatin in cyvadic-resistant soft tissue sarcoma. Eur J Cancer. 1979 Dec;15(12):1511–1513. doi: 10.1016/0014-2964(79)90032-x. [DOI] [PubMed] [Google Scholar]
  5. Fodstad O., Aamdal S., Pihl A., Boyd M. R. Activity of mitozolomide (NSC 353451), a new imidazotetrazine, against xenografts from human melanomas, sarcomas, and lung and colon carcinomas. Cancer Res. 1985 Apr;45(4):1778–1786. [PubMed] [Google Scholar]
  6. Giovanella B. C., Stehlin J. S., Jr, Shepard R. C., Williams L. J., Jr Correlation between response to chemotherapy of human tumors in patients and in nude mice. Cancer. 1983 Oct 1;52(7):1146–1152. doi: 10.1002/1097-0142(19831001)52:7<1146::aid-cncr2820520704>3.0.co;2-6. [DOI] [PubMed] [Google Scholar]
  7. Giuliani F. C., Zirvi K. A., Kaplan N. O. Therapeutic response of human tumor xenografts in athymic mice to doxorubicin. Cancer Res. 1981 Jan;41(1):325–335. [PubMed] [Google Scholar]
  8. Gottlieb J. A., Benjamin R. S., Baker L. H., O'Bryan R. M., Sinkovics J. G., Hoogstraten B., Quagliana J. M., Rivkin S. E., Bodey G. P., Sr, Rodriguez V. Role of DTIC (NSC-45388) in the chemotherapy of sarcomas. Cancer Treat Rep. 1976 Feb;60(2):199–203. [PubMed] [Google Scholar]
  9. Greenall M. J., Magill G. B., DeCosse J. J., Brennan M. F. Chemotherapy for soft tissue sarcoma. Surg Gynecol Obstet. 1986 Feb;162(2):193–198. [PubMed] [Google Scholar]
  10. Karakousis C. P., Holtermann O. A., Holyoke E. D. Cis-dichlorodiammineplatinum(II) in metastatic soft tissue sarcomas. Cancer Treat Rep. 1979 Nov-Dec;63(11-12):2071–2075. [PubMed] [Google Scholar]
  11. Klein H. O., Wickramanayake P. D., Christian E., Coerper C. Therapeutic effects of single-push or fractionated injections or continuous infusion of oxazaphosphorines (cyclophosphamide, ifosfamide, Asta Z 7557). Cancer. 1984 Sep 15;54(6 Suppl):1193–1203. doi: 10.1002/1097-0142(19840915)54:1+<1193::aid-cncr2820541317>3.0.co;2-z. [DOI] [PubMed] [Google Scholar]
  12. Mattern J., Bak M., Hahn E. W., Volm M. Human tumor xenografts as model for drug testing. Cancer Metastasis Rev. 1988 Nov;7(3):263–284. doi: 10.1007/BF00047755. [DOI] [PubMed] [Google Scholar]
  13. Mattern J., Bak M., Jr, Hoever K. H., Volm M. Development of drug resistance in a human epidermoid lung carcinoma xenograft line. Br J Cancer. 1988 Jul;58(1):30–33. doi: 10.1038/bjc.1988.155. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Moulder J. E., Hopwood L. E., Volk D. M., Davies B. M. Radiation induction of drug resistance in RIF-1: correlation of tumor and cell culture results. Int J Radiat Oncol Biol Phys. 1991 Feb;20(2):213–216. doi: 10.1016/0360-3016(91)90092-i. [DOI] [PubMed] [Google Scholar]
  15. Osieka R. Primary and acquired resistance to antineoplastic chemotherapy. A preclinical and clinical study. Cancer. 1984 Sep 15;54(6 Suppl):1168–1174. doi: 10.1002/1097-0142(19840915)54:1+<1168::aid-cncr2820541313>3.0.co;2-z. [DOI] [PubMed] [Google Scholar]
  16. Pinedo H. M., Verweij J. The treatment of soft tissue sarcomas with focus on chemotherapy: a review. Radiother Oncol. 1986 Mar;5(3):193–205. doi: 10.1016/s0167-8140(86)80049-4. [DOI] [PubMed] [Google Scholar]
  17. Samson M. K., Baker L. H., Benjamin R. S., Lane M., Plager C. Cis-dichlorodiammineplatinum(II) in advanced soft tissue and bony sarcomas: a Southwest Oncology Group Study. Cancer Treat Rep. 1979 Nov-Dec;63(11-12):2027–2029. [PubMed] [Google Scholar]
  18. Shorthouse A. J., Jones J. M., Steel G. G., Peckham M. J. Experimental combination and single-agent chemotherapy in human lung-tumour xenografts. Br J Cancer. 1982 Jul;46(1):35–44. doi: 10.1038/bjc.1982.162. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Shorthouse A. J., Smyth J. F., Steel G. G., Ellison M., Mills J., Peckham M. J. The human tumour xenograft--a valid model in experimental chemotherapy? Br J Surg. 1980 Oct;67(10):715–722. doi: 10.1002/bjs.1800671011. [DOI] [PubMed] [Google Scholar]
  20. Steel G. G., Courtenay V. D., Peckham M. J. The response to chemotherapy of a variety of human tumour xenografts. Br J Cancer. 1983 Jan;47(1):1–13. doi: 10.1038/bjc.1983.1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Stuart-Harris R. C., Harper P. G., Parsons C. A., Kaye S. B., Mooney C. A., Gowing N. F., Wiltshaw E. High-dose alkylation therapy using ifosfamide infusion with mesna in the treatment of adult advanced soft-tissue sarcoma. Cancer Chemother Pharmacol. 1983;11(2):69–72. doi: 10.1007/BF00254247. [DOI] [PubMed] [Google Scholar]
  22. Stuschke M., Budach V., Bamberg M., Budach W. Methods for analysis of censored tumor growth delay data. Radiat Res. 1990 May;122(2):172–180. [PubMed] [Google Scholar]
  23. Teicher B. A., Herman T. S., Holden S. A., Wang Y. Y., Pfeffer M. R., Crawford J. W., Frei E., 3rd Tumor resistance to alkylating agents conferred by mechanisms operative only in vivo. Science. 1990 Mar 23;247(4949 Pt 1):1457–1461. doi: 10.1126/science.247.4949.1457. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES